Table 2.
Co-mutational status for patients with TP53wt and TP53mut in advanced lung cancer.
| Variants | Total No. 139 | Patients with TP53wt, No. (%) |
Patients with TP53mut, No. (%) |
p Value (Chi-Square) |
Patients with TP53 Missense Mutations, No. (%) |
Patients with TP53 “Other Mutations,” No. (%) |
p Value (Chi-Square) |
|---|---|---|---|---|---|---|---|
| Beneficial genes | |||||||
| PBRM1 | |||||||
| Wild type | 130(93.5) | 26(86.7) | 104(95.4) | 0.085 | 66(97.1) | 38(92.7) | 0.004 |
| Mutant | 9(6.5) | 4(13.3) | 5(4.6) | 2(2.9) | 3(7.3) | ||
| KRAS | |||||||
| Wild type | 115(82.7) | 23(76.7) | 92(84.4) | 0.321 | 59(86.8) | 33(80.5) | 0.382 |
| Mutant | 24(17.3) | 7(23.3) | 17(15.6) | 9(13.2) | 8(19.5) | ||
| ARID1A | |||||||
| Wild type | 122(87.8) | 27(90.0) | 95(87.2) | 0.674 | 61(89.7) | 34(82.9) | 0.306 |
| Mutant | 17(12.2) | 3(10.0) | 14(12.8) | 7(10.3) | 7(17.1) | ||
| SMARCA4 | |||||||
| Wild type | 126(90.6) | 27(90.0) | 99(90.8) | 0.891 | 63(92.6) | 36(87.8) | 0.396 |
| Mutant | 13(9.4) | 3(10.0) | 10(9.2) | 5(7.4) | 5(12.2) | ||
| DDR pathway | |||||||
| Wild type | 54(38.8) | 12(40.0) | 42(38.5) | 0.884 | 18(26.5) | 24(58.5) | p < 0.001 |
| Mutant | 85(61.2) | 18(60.0) | 67(61.5) | 50(73.5) | 17(41.5) | ||
| Noxious genes | |||||||
| EGFR | 0.061 | 0.849 | |||||
| Wild type | 102(73.4) | 18(60.0) | 84(77.1) | 52(76.5) | 32(78.0) | ||
| Mutant | 37(26.6) | 12(40.0) | 25(22.9) | 16(23.5) | 9(22.0) | ||
| KEAP1 | |||||||
| Wild type | 124(89.2) | 29(96.7) | 95(87.2) | 0.137 | 59(86.8) | 36(87.8) | 0.875 |
| Mutant | 15(10.8) | 1(3.3) | 14(12.8) | 9(13.2) | 5(12.2) | ||
| MDM2/MDM4 | |||||||
| Amplification | 7(5.0) | 3(10.0) | 4(3.7) | 0.161 | 2(2.9) | 2(4.9) | 0.602 |
| No amplification | 132(95.0) | 27(90.0) | 105(96.3) | 66(97.1) | 39(95.1) | ||
| 11q13 | |||||||
| Amplification | 8(5.8) | 1(3.3) | 7(6.4) | 0.521 | 4(58.8) | 3(7.3) | 0.767 |
| No amplification | 131(94.2) | 29(96.7) | 102(93.6) | 64(94.1) | 38(92.7) | ||
| JAK1/JAK2 | |||||||
| Wild type | 126(90.6) | 29(96.7) | 97(89.0) | 0.201 | 62(91.2) | 35(85.4) | 0.348 |
| Mutant | 13(9.4) | 1(3.3) | 12(11.0) | 6(8.8) | 6(14.6) | ||
| CTNNB1 | |||||||
| Wild type | 133(95.7) | 27(90.0) | 106(97.2) | 0.084 | 66(97.1) | 40(97.6) | 0.877 |
| Mutant | 6(4.3) | 3(10.0) | 3(2.8) | 2(2.9) | 1(2.4) | ||
| STK11 | |||||||
| Wild type | 127(91.4) | 28(93.3) | 99(90.8) | 0.665 | 61(89.7) | 38(92.7) | 0.602 |
| Mutant | 12(8.6) | 2(6.7) | 10(9.2) | 7(10.3) | 3(7.3) | ||
| KMT2D | |||||||
| Wild type | 120(86.3) | 28(93.3) | 92(84.4) | 0.207 | 58(85.3) | 34(82.9) | 0.741 |
| Mutant | 19(13.7) | 2(6.7) | 17(15.6) | 10(14.7) | 7(17.1) | ||
| DNMT3A | |||||||
| Wild type | 133(95.7) | 29(96.7) | 104(95.4) | 0.765 | 65(95.6) | 39(95.1) | 0.911 |
| Mutant | 6(4.3) | 1(3.3) | 5(4.6) | 3(4.4) | 2(4.9) | ||
| PTEN | |||||||
| Wild type | 127(91.4) | 28(93.3) | 99(90.8) | 0.665 | 63(92.6) | 36(87.8) | 0.396 |
| Mutant | 12(8.6) | 2(6.7) | 10(9.2) | 5(7.4) | 5(12.2) |
Chromosome 11q13 amplification panel: CCND1, FGF3, FGF4, and FGF19. DDR gene panel: MLH1, MSH2, MSH6, PMS1, PMS2 (MMR); ERCC2, ERCC3, ERCC4, ERCC5 (NER); BRCA1, MER11A, NBN, RAD50, RAD51, RAD51B, RAD51D, RAD52, RAD54L (HR); BRCA2, BRIP1, FANCA, FANCC, PALB2, RAD51C, BLM (FA); ATM, ATR, CHEK1, CHEK2, MDC1 (Checkpoint); POLE, MUTHY, PARR1, RECQL4, POLD1 (Others).